Catalog No.
DHC85102
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Chimeric
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
CD37, Tspan-26, TSPAN26, Leukocyte antigen CD37, Tetraspanin-26
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P11049
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
IMGN-529, K7153A-SMCC-DM1, K7153A, CAS: 1622327-39-2
Clone ID
Naratuximab
The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models, PMID: 28753442
Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies, PMID: 29323537
EHA 2021 Virtual Congress, PMID: 34153268
In the spotlight: a novel CD37 antibody-drug conjugate, PMID: 24235129
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies, PMID: 24002446
Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study, PMID: 29453628
The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model, PMID: 24445867
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas., PMID:39374583
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine., PMID:38014209
EHA 2021 Virtual Congress., PMID:34153268
Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study., PMID:29453628
Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies., PMID:29323537
The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models., PMID:28753442
The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model., PMID:24445867
In the spotlight: a novel CD37 antibody-drug conjugate., PMID:24235129
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies., PMID:24002446
For research use only. Not for human or drug use.
